P-gp expression mediates intrinsic drug resistance in many chemotherapy-naive malignancies, such as breast, colorectal, renal, and ovarian cancers, neuroblastoma, acute myeloid leukemia (AML), non-Hodgkin’s lymphoma, and multiple myeloma [87]. Here, PGP is linked to ovarian cancer.